Blood-Based Molecular Cancer Screening Test Illustrates Challenges

Maurie Markman, MD
Published: Monday, Nov 09, 2015
Dr. Maurie Markman

Maurie Markman, MD

A company’s rather stunning recent announcement that it had developed for sale to physicians a molecular-based screening test able to detect cancer in a patient without a prior diagnosis of the malignancy prompted a very stern— and highly appropriate—response from the FDA.1 What was clearly missing in the pronouncements and advertisements from Pathway Genomics, Inc was any objective evidence that the marketed test was actually able to detect cancer, whether the assay could identify up to 10 different cancers as claimed, or whether it could find a particular type of cancer, according to the FDA.1

Further, there is no peer-reviewed evidence that any particular result on this test would impact the ability for early detection and subsequent treatment to favorably influence an overall survival outcome. Finally, and perhaps most importantly, there have apparently been no peer-reviewed reports regarding the specificity of a positive finding with this particular assay, meaning the false positive rate of the test appears to be unknown.

Of course, the substantial concern here is for the morbidity, anxiety, cost, and possibly even mortality associated with follow-up evaluation if the test result was in error and there was actually no cancer present.

Although these questions pertain to this particular test, there are broader issues at work here that bear discussion.

In some ways, this test reflects the serious problem of lead time bias in the oncology arena. This bias involves the perception that if a cancer is found at an “earlier point in time,” the patient may experience a more favorable outcome when in fact there is no change in the ultimate natural history of the illness compared with discovery of the cancer at a later date. This particular concern is highly relevant in all proposed approaches to cancer screening and early detection.

“Early” Findings Debatable

A unique issue with any blood test used to detect a solid tumor is the fundamental question of whether a positive test influences the ability to identify the cancer “early” even if the result is a true positive. This is in striking contrast to any imaging-based cancer screening approach where the anatomic location of the abnormality is evident (although the observed abnormality may not actually represent a malignancy).

For blood tests, a true positive result for the presence of cancer may be of quite limited or no clinical utility if subsequent evaluation by radiographic studies (eg, lung) or direct visualization (eg, endoscopy) is unable to identify the malignancy.

Further, the laboratory marker may result in frequent noninvasive or even invasive testing in a search for what may remain for extended periods of time solely microscopic cancer.

Beyond these technical questions, it is essential to acknowledge that there is unfortunately no inherent reason to believe that “discovering the cancer” in this manner will actually improve the patient’s survival outcome.

In fact, the particular cancers that are able to be detected by their molecular signatures in the blood may be the very cancers that metastasize early in their natural history and such screening may not be able to impact the ultimate outcome.

Of course, that statement remains speculative at this point. Appropriately conducted trials would be needed to determine whether cancer screening undertaken by this approach based on a particular blood-based molecular test is an effective strategy for the early detection of malignant disease.

A Lesson From Ovarian Cancer

Although it is not a molecular marker, the previously published experience with employing the CA-125 serum tumor antigen in the early detection of epithelial ovarian cancer is an excellent case in point regarding the potential danger of using a bloodbased test in an attempt to increase the opportunity for early detection of a nonhematologic cancer.2

Despite multiple attempts to develop an approach to employ this well-established blood test, routinely used to monitor the course of established ovarian cancer, a large-scale phase III randomized trial not only failed to demonstrated the utility of this test in the detection of early-stage disease, but also revealed that the testing strategy resulted in increased morbidity, likely due to subsequent unnecessary invasive testing.2

Prenatal Testing Exception

A critically relevant potential exception to these general statements regarding current concerns with blood-based molecular testing in the diagnosis of new cancers would be secondary molecular data that may be obtained from noninvasive prenatal testing.3

In this scenario, it is important to remember that the molecular test is being undertaken for, and is justified by, an entirely different purpose— the detection of fetal aneuploidy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication